🔎 Trials Near Me

Beranda › Kanker Lambung › Texas › Houston

Uji klinis Kanker Lambung di Houston, TX

42 studi untuk Kanker Lambung mencari peserta di lokasi sekitar Houston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • UT MD Anderson Cancer Center, Houston
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Menerima pesertaFase 2
  • The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06760819

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Menerima pesertaFase 2
  • The University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06172478

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Menerima pesertaFase 2
  • Research Site, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06219941

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Menerima pesertaFase 2
  • Research Site, Houston
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05489211

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Menerima pesertaFase 1/2
  • MD Anderson, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Menerima pesertaFase 1
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Menerima pesertaFase 1
  • Baylor College of Medicine, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213791

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT07705334

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Menerima pesertaFase 1/2
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT05267626

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Menerima pesertaFase 1
  • Oncology Consultants, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Menerima pesertaFase 1
  • MD Anderson Cancer Center - University of Texas, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06253871

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Menerima pesertaFase 1
  • UT MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06364410

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Menerima pesertaFase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07070232

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1/2
  • Research Site, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07115043

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Menerima pesertaFase 1
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT07066657

A Study of MGC026 in Participants With Advanced Solid Tumors

Menerima pesertaFase 1
  • The University of Texas MD Anderson Cancer Center, Houston
  • University of Texas Health Science Center at Houston, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT06242470

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • The University of Texas, MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626

IDOV-Immune for Advanced Solid Tumors

Menerima pesertaFase 1
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06910657

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Oncology Consultants, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT03526835

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1
  • Investigative Site #129, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jul 2026 · NCT06974110

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Menerima pesertaFase 1
  • The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
  • The University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT05208762

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Menerima pesertaFase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06131840

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Menerima pesertaFase 2
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Jul 2026 · NCT06695845

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Menerima pesertaFase 1
  • Oncology Consultants, PA, Houston
  • Oncology Consultants, PA., Houston
  • The University of Texas M.D. Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT04389632

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Menerima pesertaFase 1/2
  • MD Anderson Cancer Center, Houston
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT06710756

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Menerima pesertaFase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT05768932

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

Menerima pesertaFase 1
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT06789172

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06239194

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Menerima pesertaFase 2
  • M D Anderson Cancer Center, Houston
Usia 18 hingga 79 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT03161522

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Menerima pesertaFase 1/2
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Mar 2026 · NCT06395519

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Menerima pesertaFase 3
  • The University of Texas MD Anderson cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Feb 2026 · NCT06532006

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

Menerima pesertaFase 1
  • Baylor St. Luke's Medical Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Feb 2026 · NCT03740256

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Menerima pesertaFase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Des 2025 · NCT06943521

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Menerima pesertaStudi observasional
  • Massive Bio SYNERGY-AI site, Houston
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Menerima pesertaFase 1/2
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2025 · NCT05941507

A Study of NX-1607 in Adults With Advanced Malignancies

Menerima pesertaFase 1
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2025 · NCT05107674

Comprehensive Outcomes for After Cancer Health

Menerima pesertaSukarelawan sehat diterima
  • The University of Texas MD Anderson Cancer Center, Houston
  • UT Health Houston, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Des 2024 · NCT05349227

Uji klinis Kanker Lambung di kota lain

Studi lain di Houston

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.